As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to European Commission in 2016 about Risk Proportionate approaches in clinical trials can be found below.
As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to European Commission in 2016 about Risk Proportionate approaches in clinical trials can be found below.